17.11.2020 | Insight

UK HCPs praise efficacy of Pfizer’s COVID-19 vaccine but have concerns about practicality

By Laura Marsh

In brief:

  • Last week, Pfizer and BioNTech announce vaccine candidate.
  • UK HCPs are pleased with it’s 90% effectiveness.
  • However key concerns are consistently raised over storage and administration.
  • Highlighting the importance of understanding what your HCP audience are saying in this fast-changing landscape.
  • Keep up to date with the online HCP conversation relating to COVID-19 vaccines with the regular COVID-19 vaccine tracker.

The ongoing fight against COVID-19 has seen many companies in the pharmaceutical industry striving to develop an effective vaccine against the virus. One such effort comes from a collaboration between Pfizer and BioNTech, who announced the promising efficacy of their vaccine candidate in a press release on Monday 9th November 2020. BNT162b2 was found to be more than 90% effective in preventing COVID-19 in participants, in the first interim analysis of its global phase 3 study.

This news brings much hope to the public, with the UK government announcing that it has already procured 40 million doses of the vaccine, and stating that the NHS is ready to begin a vaccination programme in the most vulnerable once fully approved by the JCVI (Joint Committee on Vaccination and Immunisation). Within the first week after the announcement, over 2,000 UK healthcare professionals (HCPs) have offered their reactions on social media.

Amongst many posts celebrating the success of the vaccine, three key concerns were raised by UK HCPs in response to Pfizer’s vaccine announcement, which are displayed in the chart below.

Vaccine storage

The concern most frequently discussed by UK HCPs during this time was the logistical challenge of storing the vaccine, which must be kept at -70/-80 C until ready for use in patients. Those working in GP surgeries and hospitals say they do not currently have appropriate facilities to make this achievable. Others noted that this is even more of a challenge in developing nations, meaning that the vaccine is unlikely to be accessible in much of the world.

Administered by GPs

Another topic of unease for UK HCPs is the role that GPs are expected to play in administering the vaccine directly to patients. The requirements laid out by the UK government, including delivering the vaccine 7 days a week, have been described as “completely mad” by UK HCPs. Many are worried about what the implications of this will be for non COVID-19 appointments, after being told to “scale back care”. Other HCPs say that the responsibility for vaccine administration should be given to nurses or technicians, so that GPs can continue to see patients in a normal capacity.

Manufactured in Europe

HCPs have also expressed uncertainties about the practicalities of accessing Pfizer’s vaccine in the UK. As the vaccine is being manufactured in Belgium and Germany, there are concerns not only around the cold chain transportation of the vaccine across countries, but also concerns about the impact that Brexit may have upon free movement of goods into UK borders.

As the world awaits the first COVID-19 vaccine approval, and with more and more news every day around the different vaccine candidates, CREATION.CO are committed to tracking HCP reactions as the landscape develops. Keep up to date with the online HCP conversation relating to COVID-19 vaccines with our monthly COVID-19 vaccine tracker.

This article studied 5,212 posts from 2,344 UK HCP authors on social media from 8 – 15 November 2020. Data includes posts which specifically mention the Pfizer/BioNTech vaccine candidate as well as posts discussing COVID-19 vaccines generically. 

View all articles >

Meet the Author

Laura Marsh

Suggested next

Webinar: Coronavirus digital communication strategies for pharma

24.03.2020 | Article

Webinar: Coronavirus digital communication strategies for pharma

Webinar: Coronavirus digital communication strategies for pharma

By Luke Wilson

04.12.2020 | Article

What HCPs think about the 2020 NSCLC treatment landscape

What healthcare professionals think about Non-Small cell lung cancer treatment landscape

View all articles >